Plasma concentrations of persistent organic pollutants and pancreatic cancer risk.


Journal

International journal of epidemiology
ISSN: 1464-3685
Titre abrégé: Int J Epidemiol
Pays: England
ID NLM: 7802871

Informations de publication

Date de publication:
09 05 2022
Historique:
accepted: 15 05 2021
pubmed: 15 7 2021
medline: 12 5 2022
entrez: 14 7 2021
Statut: ppublish

Résumé

Findings and limitations of previous studies on persistent organic pollutants (POPs) and pancreatic cancer risk support conducting further research in prospective cohorts. We conducted a prospective case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Participants were 513 pancreatic cancer cases and 1020 matched controls. Concentrations of 22 POPs were measured in plasma collected at baseline. Some associations were observed at higher concentrations of p, p'-DDT, trans-nonachlor, β-hexachlorocyclohexane and the sum of six organochlorine pesticides and of 16 POPs. The odds ratio (OR) for the upper quartile of trans-nonachlor was 1.55 (95% confidence interval 1.06-2.26; P for trend = 0.025). Associations were stronger in the groups predefined as most valid (participants having fasted >6 h, with microscopic diagnostic confirmation, normal weight, and never smokers), and as most relevant (follow-up ≥10 years). Among participants having fasted >6 h, the ORs were relevant for 10 of 11 exposures. Higher ORs were also observed among cases with microscopic confirmation than in cases with a clinical diagnosis, and among normal-weight participants than in the rest of participants. Among participants with a follow-up ≥10 years, estimates were higher than in participants with a shorter follow-up (for trans-nonachlor: OR = 2.14, 1.01 to 4.53, P for trend = 0.035). Overall, trans-nonachlor, three PCBs and the two sums of POPs were the exposures most clearly associated with pancreatic cancer risk. Individually or in combination, most of the 22 POPs analysed did not or only moderately increased the risk of pancreatic cancer.

Sections du résumé

BACKGROUND
Findings and limitations of previous studies on persistent organic pollutants (POPs) and pancreatic cancer risk support conducting further research in prospective cohorts.
METHODS
We conducted a prospective case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Participants were 513 pancreatic cancer cases and 1020 matched controls. Concentrations of 22 POPs were measured in plasma collected at baseline.
RESULTS
Some associations were observed at higher concentrations of p, p'-DDT, trans-nonachlor, β-hexachlorocyclohexane and the sum of six organochlorine pesticides and of 16 POPs. The odds ratio (OR) for the upper quartile of trans-nonachlor was 1.55 (95% confidence interval 1.06-2.26; P for trend = 0.025). Associations were stronger in the groups predefined as most valid (participants having fasted >6 h, with microscopic diagnostic confirmation, normal weight, and never smokers), and as most relevant (follow-up ≥10 years). Among participants having fasted >6 h, the ORs were relevant for 10 of 11 exposures. Higher ORs were also observed among cases with microscopic confirmation than in cases with a clinical diagnosis, and among normal-weight participants than in the rest of participants. Among participants with a follow-up ≥10 years, estimates were higher than in participants with a shorter follow-up (for trans-nonachlor: OR = 2.14, 1.01 to 4.53, P for trend = 0.035). Overall, trans-nonachlor, three PCBs and the two sums of POPs were the exposures most clearly associated with pancreatic cancer risk.
CONCLUSIONS
Individually or in combination, most of the 22 POPs analysed did not or only moderately increased the risk of pancreatic cancer.

Identifiants

pubmed: 34259837
pii: 6321178
doi: 10.1093/ije/dyab115
pmc: PMC9082788
doi:

Substances chimiques

Environmental Pollutants 0
Pesticides 0
Polychlorinated Biphenyls DFC2HB4I0K

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

479-490

Subventions

Organisme : Medical Research Council
ID : MC_UU_00006/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the International Epidemiological Association.

Références

Environ Int. 2019 Jul;128:353-361
pubmed: 31078004
Endocr Rev. 2014 Aug;35(4):557-601
pubmed: 24483949
Biomed Pharmacother. 2007 Dec;61(10):659-64
pubmed: 17560068
Endocr Rev. 2015 Dec;36(6):E1-E150
pubmed: 26544531
Epidemiology. 2001 Mar;12(2):272-6
pubmed: 11246593
Am J Epidemiol. 2018 Mar 1;187(3):494-506
pubmed: 29106481
J Chromatogr A. 2013 Sep 27;1309:48-55
pubmed: 23972455
Cancer Causes Control. 2015 Nov;26(11):1583-91
pubmed: 26293241
Environ Res. 2019 Feb;169:417-433
pubmed: 30529143
Environ Toxicol Pharmacol. 2019 Feb;66:24-35
pubmed: 30594847
Environ Int. 2008 May;34(4):546-61
pubmed: 18054079
Nature. 2019 Mar;567(7748):305-307
pubmed: 30894741
PLoS One. 2016 Aug 10;11(8):e0160432
pubmed: 27508420
J Natl Cancer Inst. 2009 Apr 15;101(8):605-9
pubmed: 19351918
Endocr Rev. 2012 Jun;33(3):378-455
pubmed: 22419778
Environ Int. 2009 Oct;35(7):1080-5
pubmed: 19581003
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Int J Cancer. 2019 Apr 1;144(7):1511-1521
pubmed: 30178496
Natl Toxicol Program Tech Rep Ser. 2020 May;(598):
pubmed: 33556048
Gut. 2012 Nov;61(11):1583-8
pubmed: 22184070
Environ Int. 2018 May;114:334-342
pubmed: 29477570
Environ Sci Technol. 2016 Sep 20;50(18):10055-64
pubmed: 27616073
Arch Toxicol. 2016 Nov;90(11):2617-2642
pubmed: 27538405
Lancet Oncol. 2020 Mar;21(3):334-335
pubmed: 32135099

Auteurs

Miquel Porta (M)

Hospital del Mar Institute of Medical Research (IMIM PSMar), Barcelona, Catalonia, Spain.
Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.

Magda Gasull (M)

Hospital del Mar Institute of Medical Research (IMIM PSMar), Barcelona, Catalonia, Spain.
Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.

José Pumarega (J)

Hospital del Mar Institute of Medical Research (IMIM PSMar), Barcelona, Catalonia, Spain.
Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.

Hannu Kiviranta (H)

Department of Health Security, National Institute for Health and Welfare, Kuopio, Finland.

Panu Rantakokko (P)

Department of Health Security, National Institute for Health and Welfare, Kuopio, Finland.

Ole Raaschou-Nielsen (O)

Danish Cancer Society Research Center, Copenhagen, Denmark.

Ingvar A Bergdahl (IA)

Department of Biobank Research, Umeå University, Umeå, Sweden.
Occupational and Environmental Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

Torkjel Manning Sandanger (TM)

Department of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.

Antoni Agudo (A)

Unit of Nutrition and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.

Charlotta Rylander (C)

Department of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.

Therese Haugdahl Nøst (TH)

Department of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.

Carolina Donat-Vargas (C)

Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid, CEI UAM+CSIC, Madrid, Spain.

Dagfinn Aune (D)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Alicia K Heath (AK)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Lluís Cirera (L)

Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
Department of Health and Social Sciences, University of Murcia, Murcia, Spain.

Fernando Goñi-Irigoyen (F)

Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Health Department of Basque Government, Public Health Laboratory in Gipuzkoa, San Sebastian, Spain.
Health Research Institute Biodonostia, San Sebastian, Spain.

Juan Alguacil (J)

Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
University of Huelva, Huelva, Spain.

Àlex Giménez-Robert (À)

Hospital del Mar Institute of Medical Research (IMIM PSMar), Barcelona, Catalonia, Spain.
Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.

Anne Tjønneland (A)

Danish Cancer Society Research Center, Copenhagen, Denmark.

Malin Sund (M)

Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.

Kim Overvad (K)

Department of Public Health, Aarhus University, Aarhus, Denmark.

Francesca Romana Mancini (FR)

CESP, Faculté de médecine (USVQ), Université Paris-Sud, INSERM, Université Paris-Saclay, Villejuif, France.
Inserm UMR1018, Institut Gustave Roussy, Villejuif, France.

Vinciane Rebours (V)

Pancreatology Department, Beaujon Hospital, AP-HP, Clichy, France.
Inserm UMR1149, DHU Unit, Paris-Diderot University, Paris, France.

Marie-Christine Boutron-Ruault (MC)

CESP, Faculté de médecine (USVQ), Université Paris-Sud, INSERM, Université Paris-Saclay, Villejuif, France.
Inserm UMR1018, Institut Gustave Roussy, Villejuif, France.

Rudolf Kaaks (R)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Matthias B Schulze (MB)

Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam, Rehbruecke, Nuthetal, Germany.
Institute of Nutrition Science, University of Potsdam, Nuthetal, Germany.

Antonia Trichopoulou (A)

Hellenic Health Foundation, Athens, Greece.

Domenico Palli (D)

Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network-ISPRO, Florence, Italy.

Sara Grioni (S)

Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Rosario Tumino (R)

Cancer Registry and Histopathology Department, "Civic-M.P. Arezzo" Hospital, ASP Ragusa, Ragusa, Italy.

Alessio Naccarati (A)

Molecular and Genetic Epidemiology Unit, Italian Institute for Genomic Medicine (IIGM), Turin, Italy.

Salvatore Panico (S)

Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.

Roel Vermeulen (R)

Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands.

J Ramón Quirós (JR)

Public Health Directorate, Asturias, Spain.

Miguel Rodríguez-Barranco (M)

Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Escuela Andaluza de Salud Pública (EASP), Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.

Sandra M Colorado-Yohar (SM)

Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
National Faculty of Public Health, University of Antioquia, Medellín, Colombia.

María-Dolores Chirlaque (MD)

Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
Department of Health and Social Sciences, University of Murcia, Murcia, Spain.

Eva Ardanaz (E)

Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Navarra Public Health Institute, Pamplona, Spain.
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.

Nick Wareham (N)

MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Tim Key (T)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Mattias Johansson (M)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Neil Murphy (N)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Pietro Ferrari (P)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Inge Huybrechts (I)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Veronique Chajes (V)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Carlos Alberto Gonzalez (CA)

Unit of Nutrition and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.

Bas Bueno-de-Mesquita (B)

Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

Marc Gunter (M)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Elisabete Weiderpass (E)

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

Elio Riboli (E)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Eric J Duell (EJ)

Oncology Data Analytics Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.

Verena Katzke (V)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Paolo Vineis (P)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Molecular and Genetic Epidemiology Unit, Italian Institute for Genomic Medicine (IIGM), Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH